While RET fusion, BRAF V600E, and MET exon 14 skipping mutations are recommended by the NCCN as first-line therapies for advanced NSCLC, the others may serve as subsequent-line therapies after systemic treatment [15]. Here, MET is linked to non-small cell lung carcinoma.